Company Filing History:
Years Active: 1990
Title: Gustav Ammerer: Innovator in Biosynthetic Insulin Precursors
Introduction
Gustav Ammerer is a distinguished inventor based in East Seattle, WA, known for his contributions to the field of biotechnology. With a focus on biosynthetic processes, he holds a valuable patent that advances the production of human insulin.
Latest Patents
Gustav Ammerer has been awarded one patent, which pertains to a DNA-sequence encoding biosynthetic insulin precursors. The patent details a process for producing human insulin precursors, specifically highlighting human insulin derivatives that contain the peptide chain B(1-29) linked to A(1-21) via a bridging chain. This innovatory method involves transforming a yeast host with a replicable expression vehicle capable of expressing the desired DNA-sequence. Notably, the bridging chain is designed to be relatively short, consisting of 2 to 8 amino acid residues, and is structured to avoid adjacent basic amino acid residues, ensuring optimal functionality for insulin production through in vitro conversion.
Career Highlights
Gustav Ammerer is currently employed at Novo Industri A/S, a leading company in the biotechnology sector. His work has significantly contributed to advancements in insulin production, providing new methodologies that enhance efficiency and efficacy in pharmaceutical applications.
Collaborations
Throughout his career, Gustav has collaborated with esteemed colleagues, including Jan Markussen and Niels Fiil. Together, they have contributed to innovative research and development projects aimed at improving biotechnological processes, furthering the understanding and applications of insulin production.
Conclusion
Gustav Ammerer's pioneering work in biosynthetic insulin precursors marks him as a notable inventor in the realm of biotechnology. His contributions represent a significant step forward in insulin production, potentially impacting the lives of many who rely on this vital hormone for diabetes management. With continuous collaboration and innovation, Ammerer and his team are poised to lead advancements in this important field.